Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 268-610-1 | CAS number: 68131-13-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
No classification is warranted for the acute toxicity.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1986-09-04 to 1986-10-09
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Scientifically well performed study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- no
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Route of administration:
- oral: gavage
- Vehicle:
- other: Sesame oil
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 20% in 2000 mg/kg Group; 5% in 500 mg/kg Group
- Amount of vehicle (if gavage): 10 ml /kg body weight - Doses:
- 2000 mg/kg (male); 500, 2000 mg/kg (female)
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Daily during the study
- Necropsy of survivors performed: yes
- Other examinations performed:
clinical signs During the first 10, 30, 60 minutes, 2, 4 and 6 hours after the administration. Twice daily during days 1-14
body weight: On test day 0, 7 and 14 (after the administration) - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- act. ingr.
- Mortality:
- On test day 8, one female animal was found dead in 2000 mg/kg group (20% mortality)
- Clinical signs:
- other: One female that was found dead on day 8 exhibited clinical signs on day 6 and 7. No clinical sign was found in other animals during the study.
- Gross pathology:
- The animal died on day 8 was found to have light pink colored lung.
- Interpretation of results:
- study cannot be used for classification
- Remarks:
- Migrated information
- Conclusions:
- The median lethal dose of Dodigen 1481 after single oral administration to rats, observed over a period of 14 days is:
LD50 (Rat): greater than 2000 mg/kg body weight - Executive summary:
NA-DETA was given to rats per gavage at dose levels of 2000 mg/kg bw for males and 2000 and 500 mg/kg bw for females.
At 2000 mg/kg bw, one female out of five died 7 days after treatment and exhibited body weight reduction prior to death. The survived animals exhibted transiently reduced body weight gain.
No effect was found for males upon application of 2000 mg/kg bw and for females upon application of 500 mg/kg bw.No classification is warranted for the acute oral toxicity of NA-DETA
Reference
Table: Body weight development |
|||
Sex/dose level |
Initial body weight
|
Body weight gain: day 0-7 |
Body weight gain: day 7-14 |
Males/2000 mg/kg bw |
176 |
55 |
40 |
180 |
47 |
44 |
|
175 |
50 |
48 |
|
178 |
63 |
52 |
|
186 |
52 |
47 |
|
179 ± 4 (n=5) |
53 ± 6 (n=5) |
46 ± 4 (n=5) |
|
Females/2000 mg/kg bw |
175 |
16 |
9 |
172 |
28 |
22 |
|
180 |
18 |
7 |
|
180 |
17 |
15 |
|
178 |
-11 |
* |
|
177 ± 3 (n=5) |
14 ± 15 (n=5) |
13 ± 7 (n=4) |
|
Females/500 mg/kg bw |
171 |
34 |
11 |
|
173 |
26 |
11 |
|
170 |
27 |
7 |
|
179 |
31 |
15 |
|
173 |
37 |
8 |
|
173 ± 3 (n=5) |
31 ± 5 (n=5) |
10 ± 3 (n=5) |
*Found dead |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- One valid acute oral toxicity study
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Quality of whole database:
- No study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2012-06-08 to 2012-11-02
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1200 (Acute Dermal Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- (Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, München, Germany)
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - Full barrier in an air-conditioned room
- Temperature: 22 +/- 3 °C
- Relative humidity: 55 +/- 10%
- Artificial light, sequence being 12 hours light, 12 hours dark
- Air change: 10 x / hour
- Free access to Altromin 1324 maintenance diet for rats and mice (lot no. XX)
- Free access to tap water, sulphur acidified to a pH value of approximately 2.8 (drinking water, municipal residue control, microbiological controls at regular intervals)
- The animals were kept individually in IVC cages, type III H, polysulphone cages on Altromin saw fibre bedding (lot no. XX)
- Certificates of food, water and bedding are filed at BSL BIOSERVICE
- Adequate acclimatisation period (at least five days) under laboratory conditions - Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- Preparation of the Animals:
The animals were marked for individual identification by tail painting.
Approximately 24 hours before the test, the fur was removed from the dorsal area of the trunk using an electric clipper. Care was taken to avoid abrading the skin, and only animals with healthy intact skin were used.
No less than 10% of the body surface was cleared for the application.
Prior to the application a detailed clinical observation was made of all animals.
Application:
The test item was applied at a single dose, uniformly over an area which was approximately 10% of the total body surface.
The test item was held in contact with the skin by a dressing throughout a 24-hour period. The dressing consisted of a gauze-dressing and non-irritating tape and was fixed with an additional dressing in a suitable manner. - Duration of exposure:
- The test item was held in contact with the skin throughout a 24-hour period. At the end of the exposure period the residual test item was removed.
- Doses:
- The test item was applied at a single dose of 2000 mg/kg body weight to each animal.
- No. of animals per sex per dose:
- 5 male and 5 female
- Control animals:
- not required
- Details on study design:
- Observation period:
All animals were observed for 14 days after dosing
Weight Assessment:
The animals were weighed on day 1 (prior to the application) and on days 8 and 15.
Clinical Examination:
careful clinical examination was made several times on the day of dosing (at least once during the first 30 minutes and with special attention given
during the first 4 hours post-dose). As soon as symptoms were noticed they were recorded. Thereafter, the animals were observed for clinical signs once daily until the end of the observation period. All abnormalities were recorded.
Cageside observations included changes in the skin and fur, eyes and mucous membranes. Also respiratory, circulatory, autonomic and central
nervous systems and somatomotor activity and behaviour pattern were examined. Attention was directed to observations of tremors, convulsions,
salivation, diarrhoea, lethargy, sleep and coma.
Pathology:
At the end of the observation period the surviving animals were sacrificed with an overdosage of pentobarbital injected intraperitoneally (Narcoren®, Merial) at the dosage of approximately 8 mL/kg bw. All animals were subjected to gross necropsy. All gross pathological changes were recorded and in case of findings the tissues were preserved for a possible histopathological evaluation. The preserved tissues of which no histopathological
evaluation was made will be discarded 3 months after the release of the final report unless otherwise agreed upon with the sponsor.
Evaluation of Results:
Individual reactions of each animal were recorded at each time of observation.
Toxic response data were recorded by sex and dose level.
Nature, severity and duration of clinical observations were described.
The body weight changes were summarised in a tabular form.
Necropsy findings were described. - Statistics:
- According to OECD guidelines, the biological relevance of the results is the criterion for the interpretation of results, a statistical evaluation of the
results is not regarded as necessary. - Sex:
- male/female
- Dose descriptor:
- LD0
- Effect level:
- 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality was observed
- Clinical signs:
- other: No treatment-related effects were observed.
- Gross pathology:
- No treatment-related effects were observed.
- Other findings:
- Erythema grade 1 and 2 were observed in 5 of 5 male and 5 of 5 female animals. Oedema grade 1 was observed in 3 of 5 male and 4 of 5 female
animals. Oedema grade 2 was observed in 1 of 5 female animals. Eschar was observed in 5 of 5 male and 5 of 5 female animals. Wound was
observed in 2 of 5 male and 3 of 5 female animals. Necrosis was observed in 1 of 5 female animals.
All signs of irritation were not fully reversible within the observation period. - Interpretation of results:
- study cannot be used for classification
- Remarks:
- Migrated information
- Conclusions:
- Under the conditions of the present study, single dermal application of NA-DETA to rats at a dose of 2000 mg/kg body weight was associated with neither mortality nor signs of toxicity but signs of irritation.
The dermal LD50 was determined to be > 2000 mg/kg body weight. - Executive summary:
The acute dermal toxicity of NA-DETA was investigated according to the Guideline OECD 402.
NA-DETA was applied dermally to rats at dose level of 2000 mg/kg body weight. No mortality, no signs of toxicity was observed.
The dermal LD50 was determined to be > 2000 mg/kg body weight.
Reference
Table Clinical Signs of Systemic Toxicity – Individual Data - Males:
Animal |
Time of |
Observations (for Signs of Dermal Irritation, see Table 5) |
21/ male / |
during the whole observation period |
no signs of toxicity |
22/ male / |
during the whole observation period |
no signs of toxicity |
23/ male / |
during the whole observation period |
no signs of toxicity |
24/ male / |
during the whole observation period |
no signs of toxicity |
25/ male / |
during the whole observation period |
no signs of toxicity |
min = minute(s), h = hour(s), bw = body weight
Table Clinical Signs of Systemic Toxicity – Individual Data – Females:
Animal |
Time of |
Observations (for Signs of Dermal Irritation, see Table 6) |
26/ female / 2000 mg/kg bw |
during the whole observation period |
no signs of toxicity |
27/ female / 2000 mg/kg bw |
during the whole observation period |
no signs of toxicity |
28/ female / 2000 mg/kg bw |
during the whole observation period |
no signs of toxicity |
29/ female / 2000 mg/kg bw |
during the whole observation period |
no signs of toxicity |
30/ female / 2000 mg/kg bw |
during the whole observation period |
no signs of toxicity |
min = minute(s), h = hour(s), bw = body weight
Table Skin Irritation – Individual Data – Males:
Day after Start of Application |
Animal No. 21 |
Animal No. 22 |
Animal No. 23 |
Animal No. 24 |
Animal No. 25 |
|||||
E/O |
Comments |
E/O |
Comments |
E/O |
Comments |
E/O |
Comments |
E/O |
Comments |
|
day 2 |
2/0 |
nsf |
1/0 |
nsf |
2/1 |
nsf |
2/1 |
nsf |
2/1 |
nsf |
day 3 |
2/0 |
nsf |
2/0 |
nsf |
2/1 |
nsf |
2/1 |
nsf |
2/1 |
nsf |
day 4 |
2/0 |
nsf |
2/0 |
nsf |
2/1 |
nsf |
2/1 |
nsf |
2/1 |
nsf |
day 5 |
2/0 |
nsf |
2/0 |
nsf |
2/1 |
nsf |
2/1 |
nsf |
2/1 |
Es |
day 6 |
2/0 |
Es |
2/0 |
Es |
2/0 |
Es |
2/0 |
Es, W(10) |
2/0 |
Es, W(15) |
day 7 |
2/0 |
Es |
2/0 |
Es |
2/0 |
Es |
2/0 |
Es, W(10) |
2/0 |
Es, W(10) |
day 8 |
1/0 |
Es |
2/0 |
Es |
2/0 |
Es |
1/0 |
Es |
1/0 |
Es |
day 9 |
1/0 |
Es |
2/0 |
Es |
2/0 |
Es |
1/0 |
Es |
1/0 |
Es |
day 10 |
1/0 |
Es |
1/0 |
Es |
2/0 |
Es |
1/0 |
Es |
1/0 |
Es |
day 11 |
1/0 |
Es |
1/0 |
Es |
2/0 |
Es |
1/0 |
Es |
1/0 |
Es |
day 12 |
1/0 |
Es |
1/0 |
Es |
2/0 |
Es |
1/0 |
Es |
1/0 |
Es |
day 13 |
1/0 |
Es |
0/0 |
Es |
1/0 |
Es |
1/0 |
Es |
1/0 |
Es |
day 14 |
1/0 |
Es |
0/0 |
Es |
1/0 |
Es |
1/0 |
Es |
1/0 |
Es |
day 15 |
1/0 |
Es |
0/0 |
Es |
1/0 |
Es |
1/0 |
Es |
1/0 |
Es |
Comments: E = erythema; O = oedema; 1, 2, 3, 4 = scoring system laid down in OECD Guideline 404 (Table 2) Es = eschar; W (Ømm) = wound; nsf = no specific findings
|
Table Skin Irritation – Individual Data – Females:
Day after Start of Application |
Animal No. 26 |
Animal No. 27 |
Animal No. 28 |
Animal No. 29 |
Animal No. 30 |
|||||
E/O |
Comments |
E/O |
Comments |
E/O |
Comments |
E/O |
Comments |
E/O |
Comments |
|
day 2 |
2/0 |
nsf |
2/1 |
nsf |
1/0 |
nsf |
2/0 |
nsf |
2/1 |
nsf |
day 3 |
2/1 |
nsf |
2/2 |
nsf |
1/0 |
nsf |
2/1 |
* |
2/1 |
nsf |
day 4 |
2/1 |
nsf |
2/2 |
nsf |
1/0 |
nsf |
2/1 |
* |
2/1 |
nsf |
day 5 |
2/1 |
nsf |
2/0 |
Es, |
1/0 |
nsf |
2/1 |
* |
2/1 |
nsf |
day 6 |
2/0 |
N (15) |
2/1 |
Es, |
2/0 |
Es, |
2/1 |
Es, * |
2/0 |
W (2.5 cm) |
day 7 |
2/0 |
N (15) |
2/1 |
Es, |
2/0 |
Es, |
2/1 |
Es, * |
2/0 |
W (2.5 cm) |
day 8 |
2/0 |
N (15) |
2/0 |
Es |
2/0 |
Es |
2/1 |
Es, * |
2/0 |
W (2.5 cm) |
day 9 |
2/0 |
Es, N (15) |
2/0 |
Es |
2/0 |
Es |
2/0 |
Es, * |
2/0 |
W (2.5 cm) |
day 10 |
2/0 |
Es, N (15) |
2/0 |
Es |
2/0 |
Es |
2/0 |
Es, * |
2/0 |
Es, |
day 11 |
2/0 |
Es, N (15) |
2/0 |
Es |
2/0 |
Es |
2/0 |
Es |
2/0 |
Es, |
day 12 |
2/0 |
Es, N (15) |
2/0 |
Es, |
2/0 |
Es |
2/0 |
Es |
2/0 |
Es |
day 13 |
1/0 |
Es |
2/0 |
Es, |
1/0 |
Es |
1/0 |
Es |
1/0 |
Es |
day 14 |
1/0 |
Es |
1/0 |
Es, |
1/0 |
Es |
1/0 |
Es |
1/0 |
Es |
day 15 |
1/0 |
Es |
1/0 |
Es |
1/0 |
Es |
1/0 |
Es |
1/0 |
Es |
Comments: E = erythema; O = oedema; 1, 2, 3, 4 = scoring system laid down in OECD Guideline 404 (Table 2) Es = eschar; N (Ømm) = necrosis; W (Ø) = wound; nsf = no specific findings; * = animal very nervous
|
Table Absolute Body Weights in g and Body Weight Gain in %:
Dose: 2000 mg/kg body weight |
||||
Animal No. / Sex |
g |
g |
g |
% |
21 / male |
238 |
243 |
276 |
16 |
22 / male |
245 |
262 |
291 |
19 |
23 / male |
232 |
220 |
249 |
7 |
24 / male |
231 |
230 |
261 |
13 |
25 / male |
241 |
238 |
261 |
8 |
26 / female |
223 |
220 |
220 |
-1 |
27 / female |
211 |
198 |
209 |
-1 |
28 / female |
210 |
205 |
215 |
2 |
29 / female |
221 |
214 |
220 |
0 |
30 / female |
212 |
205 |
216 |
2 |
Table Macroscopic Findings - Individual Data – Males and Females:
Dose: 2000 mg/kg bw |
||
Animal No. / |
Organ |
Macroscopic Findings |
21 / male |
- |
nsf |
22 / male |
- |
nsf |
23 / male |
- |
nsf |
24 / male |
- |
nsf |
25 / male |
liver |
liver partially located in thorax |
26 / female |
- |
nsf |
27 / female |
- |
nsf |
28 / female |
- |
nsf |
29 / female |
- |
nsf |
30 / female |
- |
nsf |
nsf = no specific findings
Table LD50:
Dose (Unit)
|
Number of Animals Investigated |
Number of Intercurrent Deaths |
LD50 |
2000 mg/kg bw |
5 males |
0 |
> 2000 mg/kg bw |
2000mg/kg bw |
5 females |
0 |
> 2000 mg/kg bw |
bw = body weight
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- One valid acute dermal toxicity study.
Additional information
Justification for classification or non-classification
The LD50 for acute toxicity in rats was found to be higher than 2000 mg/kg bw for the oral and dermal exposure routes. No significant hazard can be reliably derived for inhalation routes. No classification is warranted for the acute toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.